-
公开(公告)号:US20230310544A1
公开(公告)日:2023-10-05
申请号:US17709731
申请日:2022-03-31
申请人: Alexandre Vasilievich Ivachtchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk , ASAVI LLC
发明人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Ilya Andreevich Ivashchenko , Nikolay Filippovich Savchuk
IPC分类号: A61K38/17 , A61P31/14 , A61P31/16 , A61K31/4965 , A61K31/196 , A61K31/351
CPC分类号: A61K38/1709 , A61P31/14 , A61P31/16 , A61K31/4965 , A61K31/196 , A61K31/351
摘要: A pharmaceutical combination prevention and treatment of RNA virus infection and/or a disease associated with this infection, of acute respiratory viral infections (ARVI) and severe acute respiratory syndrome (SARS), including viral and bacterial pneumonia and COVID-19, using aprotinin (APR) and an anti-RNA ingredient. A pharmaceutical kit and pharmaceutical composition in the form of an aqueous solution (APC) or a lyophilizate (PCL) for a pharmaceutical combination treatment and prevention of RNA virus infection and/or a disease associated with this infection.
-
公开(公告)号:US20230310480A1
公开(公告)日:2023-10-05
申请号:US17709608
申请日:2022-03-31
申请人: Alexandre Vasilievich Ivachtchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk , ASAVI LLC
发明人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Ilya Andreevich Ivashchenko , Nikolay Filippovich Savchuk
IPC分类号: A61K31/7068 , A61K38/57 , A61K45/06
CPC分类号: A61K31/7068 , A61K38/57 , A61K45/06
摘要: The application relates to pharmaceutical combinations, methods, and therapies for the treatment and prevention of SARS-CoV-2 infection and related diseases. The combinations contain aprotinin and molnupiravir, and/or favipiravir. The application also includes related pharmaceutical kits. Further details are described in the specification.
-
3.
公开(公告)号:US20180030080A1
公开(公告)日:2018-02-01
申请号:US15221613
申请日:2016-07-28
申请人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Nikolay Filippovich Savchuk , Alena Alexandrovna Ivachtchenko , Oleg Dmitrievich Mitkin , ASAVI, LLC
发明人: Alexandre Vasilievich Ivachtchenko , Oleg Dmitrievich Mitkin , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk
IPC分类号: C07H19/16 , C07H19/06 , C07F9/6558 , C07F9/6561
CPC分类号: C07H19/16 , A61P31/12 , A61P35/00 , C07F9/65586 , C07F9/65616 , C07H19/06 , C07H19/10 , C07H19/20
摘要: The present invention pertains to chemotherapeutic agents and their use for treating viral and cancerous diseases. These compounds are inhibitors of HCV NS5B polymerase, HBV DNA polymerase and, HIV-1 reverse transcriptase (RT) inhibitor, and for treatment of hepatitis B and C infection in mammals. These compounds are also of interest for the treatment of cancer.The phosphoramidate nucleoside prodrug of the general formula 1, a stereoisomer, isotope-enriched analogue, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, wherein: Ar is aryl or hetaryl; R1 is H or CH3; R2 is the substituent selected from OCH2CH═CH2, OCH2CH≡CH, OCH2CH2CH2OCH3, R3 is H or CH3; R4 is OH, OR5, NR6R7; R5 is C1-C4-alkyl; R6 and R7 are not necessarily the same substituents selected from H or CH3; Z═O, or NH; an arrow (→) indicates the place of substituent connection; Nuc is R8 and R9 are not necessarily the same substituents selected from H, F, Cl, CH3 or OH provided when continuous line and its accompanying dotted line () together are the single carbon-carbon (C—C) bond or R8 and R9 are hydrogen provided when continuous line and its accompanying dotted line () together are the double carbon-carbon bond (C═C); R10 is the substituent selected from R10.1-R10.5; R11 is the substituent selected from H, F, Cl, CH3, or CF3; R12 is hydrogen, C1-C4-alkyl or C3-C6-cycloalkyl; X is oxygen or ethanediyl-1,1 (C═CH2); Y is O, S, CH2, or HO—CH group provided when continuous line and its accompanying dotted line () together are the single carbon-carbon (C—C) bond or Y is CH group provided when continuous line and its accompanying dotted line () together are the double carbon-carbon bond (C═C), and compound of the general formula 1, stereoisomers, isotope-enriched analogues, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, wherein: Ar is aryl or hetaryl; R1 is H or CH3; R is isopropyl; Nuc is
-
公开(公告)号:US20230310467A1
公开(公告)日:2023-10-05
申请号:US17709609
申请日:2022-03-31
申请人: Alexandre Vasilievich Ivachtchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk , ASAVI LLC
发明人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Ilya Andreevich Ivashchenko , Nikolay Filippovich Savchuk
IPC分类号: A61K31/675 , A61K31/519 , A61K38/57 , A61P31/14
CPC分类号: A61K31/675 , A61K31/519 , A61K38/57 , A61P31/14
摘要: The application relates to pharmaceutical combinations, methods, and therapies for the treatment and prevention of SARS-CoV-2 infection and related diseases. The combinations contain aprotinin, baricitinib, and/or remdesivir. The application also includes related pharmaceutical kits. Further details are described in the specification.
-
公开(公告)号:US20230346899A1
公开(公告)日:2023-11-02
申请号:US18298056
申请日:2023-04-10
申请人: Alexandre Vasilievich Ivachtchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk , ASAVI LLC
发明人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Ilya Andreevich Ivashchenko , Nikolay Filippovich Savchuk
IPC分类号: A61K38/57 , A61K31/427 , A61P31/14 , A61K31/403
CPC分类号: A61K38/57 , A61K31/403 , A61K31/427 , A61P31/14
摘要: The present application relates to the new the pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including viral and bacterial pneumonia and COVID-19, using aprotinin (APR), ribavirin and / or nirmatrelvir (NIMR), the pharmaceutical kit and the pharmaceutical composition for this pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19.
-
公开(公告)号:US11648300B1
公开(公告)日:2023-05-16
申请号:US17709727
申请日:2022-03-31
申请人: ASAVI LLC , Alexandre Vasilievich Ivachtchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk
发明人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Ilya Andreevich Ivachtchenko , Nikolay Filippovich Savchuk
IPC分类号: A61K38/57 , A61P31/14 , A61K31/427 , A61K31/403
CPC分类号: A61K38/57 , A61K31/403 , A61K31/427 , A61P31/14
摘要: The present application relates to the new the pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including viral and bacterial pneumonia and COVID-19, using aprotinin (APR), ribavirin and/or nirmatrelvir (NIMR), the pharmaceutical kit and the pharmaceutical composition for this pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19.
-
公开(公告)号:US10266558B2
公开(公告)日:2019-04-23
申请号:US15287805
申请日:2016-10-07
申请人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Nikolay Filippovich Savchuk , ASAVI, LLC , Alena Alexandrovna Ivachtchenko , Oleg Dmitrievich Mitkin
发明人: Alexandre Vasilievich Ivachtchenko , Oleg Dmitrievich Mitkin , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk
IPC分类号: A61K31/70 , A01N43/04 , C07H19/10 , A61K31/7072 , A61K45/06 , A61K31/7068 , A61K31/7076 , A61K31/708 , A61K31/7064 , A61K31/7056 , A61K31/706 , A61K31/7084 , A61K31/7052
摘要: Nucleosides and nucleotides (nucleos(t)ides) have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with viral infections or cancer. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Therefore nucleos(t)ide are of great interest as promising chemotherapeutic agents, including: 2′-deoxy-L-uridine (CAS 31501-19-6), 2′-deoxy-D-uridine (CAS 951-78-0), telbivudine (CAS 3424-98-4), zidovudine (AZT, CAS 30516-87-1), trifluridine (CAS 70-00-8), clevudine (CAS 163252-36-6), PSI-6206 (CAS 863329-66-2), 2′-(S)-2′-chloro-2′-deoxy-2′-fluorouridine (CAS 1673560-41-2), ND06954 (CAS 114248-23-6), stavudine (CAS 3056-17-5), 5-ethynyltavudine (Festinavir, CAS 634907-30-5), torcitabine (CAS 40093-94-5), (−)-beta-D-(2R,4R)-dioxolane-thymine (DOT, 1-((2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methyl-2,4(1H,3H)-pyrimidinedione, CAS No. 127658-07-5), 2-(6-amino-purin-9-yl)-ethanol (CAS 707-99-3), 2′-C-methylcytidine (CAS 20724-73-6), PSI-6130 (CAS 817204-33-4), gemcitabine (CAS 95058-81-4), 2′-chloro-2′-deoxy-2′-fluorocytidine (CAS 1786426-19-4), 2′,2′-dichloro-2′-deoxycytidine (CAS 1703785-65-2), 2′-C-methylcytidine (CAS 20724-73-6), PSI-6130 (CAS 817204-33-4), lamivudine (3TC, CAS 134678-17-4), emtricitabine (CAS 143491-57-0), 2′-deoxyadenosine (CAS 958-09-8), 2′-deoxy-β-L-adenosine (CAS 14365-45-8), 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine (CAS 865363-93-5), didanosine (CAS 69655-05-6), entecavir (CAS 209216-23-9), FMCA (CAS 1307273-70-6), dioxolane-G (DOG, CAS 145514-01-8), β-D-2′-deoxy-2′-(R)-fluoro-2′-β-C-methylguanosine (CAS No 817204-45-8), abacavir (ABC, CAS 136470-78-5), dioxolane-A (DOA, CAS #145514-02-9), [(2R,4R)-4-(6-cyclopropylamino-purin-9-yl)-[1,3]dioxolan-2-yl]-methanol (CAS 1446751-04-7), amdoxovir (AMDX, CAS 145514-04-1), (R)-1-(6-amino-purin-9-yl)-propan-2-ol (CAS 14047-28-0), and [(2S,5R)-5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yl]-methanol.Macroheterocyclic nucleoside derivative and its analog of the general formula 1 or general formula 2, a stereoisomer, isotope-enriched analog, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, wherein: Ar is aryl or hetaryl; R1 and R2 are not necessarily the same substituents selected from H, F, Cl, CH3, OH; R3 is H or CH3; X is oxygen or ethanediyl-1,1 (C═CH2); Y is CH(R4)(CH2)k, CH(R4)(CH2)mC(O)O(CH2)n; R4 is H or CH3; k has a value from zero to six; m has a value from zero to two; n has a value of one to four; Q is a radical selected from Q1-Q4; wherein: R5 is the substituent selected from H, F, Cl, CH3, OH; the arrow (→) indicates the location, joined by Q1-Q4.
-
8.
公开(公告)号:US20180099989A1
公开(公告)日:2018-04-12
申请号:US15287805
申请日:2016-10-07
申请人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Nikolay Filippovich Savchuk , Alena Alexandrovna Ivachtchenko , Oleg Dmitrievich Mitkin , ASAVI, LLC
发明人: Alexandre Vasilievich Ivachtchenko , Oleg Dmitrievich Mitkin , Andrey Alexandrovich Ivashchenko , Alena Alexandrovna Ivachtchenko , Nikolay Filippovich Savchuk
IPC分类号: C07H19/10 , A61K45/06 , A61K31/7072
CPC分类号: C07H19/10 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K45/06 , A61K2300/00
摘要: Nucleosides and nucleotides (nucleos(t)ides) have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with viral infections or cancer. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Therefore nucleos(t)ide are of great interest as promising chemotherapeutic agents, including: 2′-deoxy-L-uridine (CAS No 31501-19-6), 2′-deoxy-D-uridine (CAS No 951-78-0), telbivudine (CAS No 3424-98-4), zidovudine (AZT, CAS No 30516-87-1), trifluridine (CAS No 70-00-8), clevudine (CAS No 163252-36-6), PSI-6206 (CAS No 863329-66-2), 2′-(5)-2′-chloro-2′-deoxy-2′-fluorouridine (CAS No 1673560-41-2), ND06954 (CAS No 114248-23-6), stavudine (CAS No 3056-17-5), 5-ethynyltavudine (Festinavir, CAS No 634907-30-5), torcitabine (CAS No 40093-94-5), (−)-beta-D-(2R,4R)-dioxolane-thymine (DOT, 1-((2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methyl-2,4 (1H,3H)-pyrimidinedione, CAS No. 127658-07-5), 2-(6-amino-purin-9-yl)-ethanol (CAS No 707-99-3), 2′-C-methylcytidine (CAS No 20724-73-6), PSI-6130 (CAS No 817204-33-4), gemcitabine (CAS No 95058-81-4), 2′-chloro-2′-deoxy-2′-fluorocytidine (CAS No 1786426-19-4), 2′,2′-dichloro-2′-deoxycytidine (CAS No 1703785-65-2), 2′-C-methylcytidine (CAS No 20724-73-6), PSI-6130 (CAS No 817204-33-4), lamivudine (3TC, CAS No 134678-17-4), emtricitabine (CAS No 143491-57-0), 2′-deoxyadenosine (CAS No 958-09-8), 2′-deoxy-β-L-adenosine (CAS No 14365-45-8), 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine (CAS No 865363-93-5), didanosine (CAS No 69655-05-6), entecavir (CAS No 209216-23-9), FMCA (CAS No 1307273-70-6), dioxolane-G (DOG, CAS No 145514-01-8), β-D-2′-deoxy-2′-(R)-fluoro-2′-β-C-methylguanosine (CAS No 817204-45-8), abacavir (ABC, CAS No 136470-78-5), dioxolane-A (DOA, CAS #145514-02-9), [(2R,4R)-4-(6-cyclopropylamino-purin-9-yl)-[1,3]dioxolan-2-yl]-methanol (CAS No 1446751-04-7), amdoxovir (AMDX, CAS No 145514-04-1), (R)-1-(6-amino-purin-9-yl)-propan-2-ol (CAS No 14047-28-0), and [(2S,5R)-5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yl]-methanol.Macroheterocyclic nucleoside derivative and its analogue of the general formula 1 or general formula 2, a stereoisomer, isotope-enriched analogue, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, wherein: Ar is aryl or hetaryl; R1 and R2 are not necessarily the same substituents selected from H, F, Cl, CH3, OH; R3 is H or CH3; X is oxygen or ethanediyl-1,1 (C═CH2); Y is CH(R4)(CH2)k, CH(R4)(CH2)mC(O)O(CH2)n; R4 is H or CH3; k has a value from zero to six; m has a value from zero to two; n has a value of one to four; Q is a radical selected from Q1-Q4; wherein: R5 is the substituent selected from H, F, Cl, CH3, OH; the arrow (→) indicates the location, joined by Q1-Q4.
-
公开(公告)号:US20190054109A1
公开(公告)日:2019-02-21
申请号:US15745152
申请日:2017-04-07
申请人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Nikolay Filippovich Savchuk , Alena Alexandrovna Ivachtchenko , Alexandre Vasilievich IVACHTCHENKO , ALLA CHEM, LLC
IPC分类号: A61K31/7072 , A61P31/14 , A61K45/06 , A61K31/403 , A61K31/4709
摘要: The present invention relates to an antiviral composition and a method for application thereof in the treatment of hepatitis C virus.Said antiviral composition comprises the HCV NS5B inhibitor of general formula 1, or a stereoisomer, an isotopically enriched analog, or crystalline or polycrystalline forms thereof.
-
公开(公告)号:US20230181704A1
公开(公告)日:2023-06-15
申请号:US17045538
申请日:2020-07-03
申请人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Nikolay Filippovich Savchuk , Alena Alexandrovna Ivachtchenko , Vladimir Grigorievich Loginov , Mikhail Topr
发明人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Nikolay Filippovich Savchuk , Alena Alexandrovna Ivachtchenko , Vladimir Grigorievich Loginov , Mikhail Topr
摘要: This invention relates to a novel anti-SARS-CoV-2 virus agent Antiprovir to be used for the prevention and treatment of coronavirus disease COVID-19.
The use of a pharmaceutical composition, including Aprotex®, Gordox® and Aerus®, with aprotinin as the active ingredient and excipients, said pharmaceutical composition being anti-SARS-CoV-2 virus drug Antiprovir to be used for the prevention and treatment of coronavirus disease COVID-19.
The drug Antiprovir for the prevention and treatment of coronavirus disease COVID-19, which is a pharmaceutical composition containing 0.1% wt. ÷ 0.2% wt. aprotinin, optionally 0.2 %wt. ÷ 1.0% wt. excipients, and the rest is water for injection.
-
-
-
-
-
-
-
-
-